Skip to main content
. Author manuscript; available in PMC: 2016 Dec 1.
Published in final edited form as: Neurogastroenterol Motil. 2015 Sep 20;27(12):1721–1735. doi: 10.1111/nmo.12668

Figure 4.

Figure 4

Comparison of the in vivo effects of the cannabinoid agonists AM841 and WIN 55,212-2 on rat gastrointestinal motor function. Motor function was measured by radiological methods (see text). Vehicle (30 μl kg−1 of Tocrisolve® in saline solution), AM841 (AM, 0.1 mg kg−1) or WIN 55,212-2 (WIN, 5 mg kg−1) were intraperitoneally injected, and barium sulfate (2.5 mL, 2 g mL−1) was intragastrically administered immediately afterwards. X-rays were taken 0, 1, 2, 4, 6 and 8 h after barium administration. Data represent mean ± SEM for motor function in stomach, small intestine, caecum and colorectum (panel A). N ≥ 6, each group. **p <0.01, ***p <0.001 vs vehicle (two-way ANOVA followed by Bonferroni post-hoc test). Panel B: Representative X-rays of rats treated with AM (0.1 mg kg−1) or WIN (5 mg kg−1), obtained 0, 2, 4 and 8 h after barium. Scale bar: 4 cm.